Q4 Earnings Announcements…
That’s right… Q4 earnings announcements are coming… And these five microcap stocks appear to be in an excellent position to see a surge in share price.
>>> Click here to see all 5 stocks
David W. Boyer net worth and biography

David Boyer Biography and Net Worth

David W. Boyer was appointed Chief Corporate Affairs Officer in September 2019 and is responsible for patient advocacy and engagement, corporate communications, government relations, and public policy at Neurocrine Biosciences. Mr. Boyer brings nearly 20 years of experience in public affairs, specializing in the life sciences and biopharmaceutical sectors. He joins Neurocrine Biosciences after nine years with the BGR Group, where he served as a Principal and the Head of the Health & Lifesciences Practice, leading the firm’s healthcare advocacy, policy and strategy development, and strategic consulting team. During his tenure at the BGR Group, Mr. Boyer led public policy, advocacy, and strategic communications initiatives for a wide range of healthcare clients. Prior to joining the BGR Group, Mr. Boyer served as Special Assistant to the President for Legislative Affairs under President George W. Bush, Assistant Commissioner for Legislation at the U.S. Food and Drug Administration, and Special Assistant to the Secretary at the U.S. Department of Health and Human Services. In addition to his public service, Mr. Boyer held senior advocacy positions at the Biotechnology Innovation Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA). Mr. Boyer holds a B.A. in Government from Georgetown University.

What is David W. Boyer's net worth?

The estimated net worth of David W. Boyer is at least $532,270.34 as of October 3rd, 2022. Mr. Boyer owns 4,214 shares of Neurocrine Biosciences stock worth more than $532,270 as of December 2nd. This net worth evaluation does not reflect any other assets that Mr. Boyer may own. Learn More about David W. Boyer's net worth.

How do I contact David W. Boyer?

The corporate mailing address for Mr. Boyer and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected] Learn More on David W. Boyer's contact information.

Has David W. Boyer been buying or selling shares of Neurocrine Biosciences?

In the last ninety days, David W. Boyer has sold $153,169.83 in shares of Neurocrine Biosciences stock. Most recently, David W. Boyer sold 1,437 shares of the business's stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $106.59, for a transaction totalling $153,169.83. Following the completion of the sale, the insider now directly owns 4,214 shares of the company's stock, valued at $449,170.26. Learn More on David W. Boyer's trading history.

Who are Neurocrine Biosciences' active insiders?

Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.

Are insiders buying or selling shares of Neurocrine Biosciences?

During the last year, insiders at the sold shares 23 times. They sold a total of 250,459 shares worth more than $26,162,165.04. The most recent insider tranaction occured on November, 30th when insider Eric Benevich sold 50,000 shares worth more than $6,295,000.00. Insiders at Neurocrine Biosciences own 4.4 % of the company. Learn More about insider trades at Neurocrine Biosciences.

Information on this page was last updated on 11/30/2022.

David W. Boyer Insider Trading History at Neurocrine Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/3/2022Sell1,437$106.59$153,169.834,214View SEC Filing Icon  
2/7/2022Sell240$81.07$19,456.80View SEC Filing Icon  
See Full Table

David W. Boyer Buying and Selling Activity at Neurocrine Biosciences

This chart shows David W Boyer's buying and selling at Neurocrine Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Neurocrine Biosciences Company Overview

Neurocrine Biosciences logo
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL - Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $126.31
Low: $125.65
High: $129.29

50 Day Range

MA: $114.32
Low: $100.57
High: $127.06

2 Week Range

Now: $126.31
Low: $71.88
High: $129.29


654,328 shs

Average Volume

795,103 shs

Market Capitalization

$12.14 billion

P/E Ratio


Dividend Yield



Bear Market Expert Reveals His #1 Stock for November 2023 
"I went from the brink of bankruptcy to wealthy – thanks to one type of stock". Get his top pick here.